The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics

Rivera-Caraballo, Kimberly; Nair, Mitra; Lee, Tae Jin; Kaur, Balveen; Yoo, Ji Young

doi:10.1016/j.omto.2022.05.013

Cited by 6 publications

(3 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integrins are involved in most resistance mechanisms of GBM, becoming a potential therapeutic target, with several completed and ongoing clinical trials [ 160 , 161 ]. Integrins are a type of transmembrane receptor and cell adhesion molecules composed of two subunits, α and β.…”

Section: New Therapies For the Treatment Of Gbmmentioning

confidence: 99%

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

Yalamarty

Filipczak

et al. 2023

Cancers

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood–brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to reduced effectiveness. Despite these challenges, there are several treatment options available for GBM. The standard of care for newly diagnosed GBM patients involves surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. Emerging treatments include immunotherapy, such as checkpoint inhibitors, and targeted therapies, such as bevacizumab, that attempt to attack specific vulnerabilities in GBM cells. Another promising approach is the use of tumor-treating fields, a type of electric field therapy that has been shown to slow the growth of GBM cells. Clinical trials are ongoing to evaluate the safety and efficacy of these and other innovative treatments for GBM, intending to improve with outcomes for patients.

show abstract

Section: New Therapies For the Treatment Of Gbmmentioning

confidence: 99%

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

Yalamarty

Filipczak

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Remarkably, the triple therapy was able to remodel the tight tumor stroma, which normally supports tumor growth, allowing increased trafficking of immune effector CD8 T cells and CD4 T helper cells, and reduced infiltration by myeloid suppressor cells, overall enhancing the effects of the anti-tumor immunity prompted by the oHSV. The lack of efficacy of dual oHSV plus ICB therapy in these tumors with a supporting dense stroma makes it increasingly apparent that it is essential to act on TME structure and signaling, e.g., along the integrin axis, for successful immunovirotherapy [89].…”

Section: Next-generation Combination Therapies To Improve Ov Efficacymentioning

confidence: 99%

Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis

Menotti,

Vannini

2023

IJMS

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are the frontier therapy for refractory cancers, especially in integration with immunomodulation strategies. In cancer immunovirotherapy, the many available “omics” and systems biology technologies generate at a fast pace a challenging huge amount of data, where apparently clashing information mirrors the complexity of individual clinical situations and OV used. In this review, we present and discuss how currently big data analysis, on one hand and, on the other, simulation, modeling, and computational technologies, provide invaluable support to interpret and integrate “omic” information and drive novel synthetic biology and personalized OV engineering approaches for effective immunovirotherapy. Altogether, these tools, possibly aided in the future by artificial intelligence as well, will allow for the blending of the information into OV recombinants able to achieve tumor clearance in a patient-tailored way. Various endeavors to the envisioned “synthesis” of turning OVs into personalized theranostic agents are presented.

show abstract

“…Interestingly, while integrins are important for virus entry, their activation can also promote anti-viral signaling in the tumor microenvironment (TME), 6 and their inhibition promotes oncolysis. 7 Blockade of integrin activation with Cilengitide and integrin-blocking antibodies has been reported to improve the outcome of virotherapy in preclinical models. 8 , 9 Here, Yamada et al.…”

mentioning

confidence: 99%

Triple combination therapy for pancreatic cancer remodels stroma and improves survival

Vázquez-Arreguín

Kaur

2023

Molecular Therapy - Oncolytics

Self Cite

View full text Add to dashboard Cite

The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics

Cited by 6 publications

References 116 publications

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis

Triple combination therapy for pancreatic cancer remodels stroma and improves survival

Contact Info

Product

Resources

About